Todos Medical Releases Preliminary Data from IRB Exempt Tollovid® Market Study in Acute and Prolonged COVID

83% of respondents with acute COVID were satisfied

68% of respondents with long COVID were satisfied

NEW YORK, NY, and TEL AVIV, ISRAEL, June 23, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced preliminary data from ongoing IRB-sponsored and delivered market research of its majority-owned joint venture 3CL Pharma Ltd. Of the 41 first responders, 78% of whom were fully vaccinated against COVID-19, 13 said they started using Tollovid when they were diagnosed with active COVID infection, while 28 respondents said they used Tollovid for treat their long COVID symptoms. 15 of the long COVID respondents had had symptoms for up to 9 months (COVID “short” long), and 12 of the long COVID respondents reported having symptoms for more than 9 months (COVID long “chronic”). 18 of the 24 respondents who answered the question “Who diagnosed your Long COVID?” indicated that they had been diagnosed by a medical professional. The preliminary results of the market research are shown in the table below:

* Tollovid® is not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID

“We are pleased with the preliminary results of this sponsored market research which show that the majority of our customers are satisfied with Tollovid,” said Dr. Dorit Arad, Founder and Chief Scientific Officer of 3CL Pharma. “As we add to the growing body of information related to COVID, Long COVID and 3CL protease inhibitors products, we believe that the insights gained from this market research will enable us to tailor our offering to meet the needs of immunocompetent individuals. (non-immune compromised) and Long COVID communities, which currently have no 3CL protease inhibitor options on the market.

“Lessons learned from the use of our dietary supplement Tollovid will also allow us to design future long-chronic COVID clinical trials for our therapeutic drug candidate Tollovir™, which is currently being prepared to enter a pivotal Phase 2 clinical study/ 3 in hospitalized COVID. patients,” said Gerald Commissiong, CEO of Todos Medical and interim CEO of 3CL Pharma. “Due to Tollovid’s status as a dietary supplement in the US market, we have a huge strategic advantage over Long COVID’s competitors because we are able to listen to patients describe first-hand how Tollovid supplementation , alone or sometimes in combination with other products, helps them and applies this knowledge to our formal Tollovir Long COVID drug development plans.

Market research survey respondents generally followed Tollovid label directions, taking 12 capsules daily for 5 days among Acute COVID respondents, and taking at least 2 bottles of Tollovid as directed among Long COVID respondents. This market research is not designed to assess the optimal dosage of Tollovid. No negative effects from interactions with other concomitant medications or supplements were reported by survey respondents.

To purchase Tollovid, please visit Amazon Where www.MyTollovid.com.

About Tollovid® and Tollovid Daily™

Tollovid and Tollovid Daily are dietary supplements made from natural ingredients that help support and maintain healthy immune function and also have potent 3CL protease inhibiting properties based on in vitro functional tests that show strong inhibition of 3CL protease activity. Tollovid’s IC50 3CL protease binding affinity is at least ten times (10x) higher than the IC50 3CL protease binding affinity published by Ivermectin. The IC50 binding affinity of Tollovid Daily’s 3CL protease is at least two and a half times (2.5x) that of ivermectin. Tollovid and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day which provides maximum immune support. Tollovid Daily is a daily immune support product with a twice daily dosing schedule.

About Tollovir®

Tollvir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the intervention of the Nidovirus group of viruses which includes coronaviruses such as SARS-CoV-2, COVID-19, SARS-CoV-1, the MERS and the 229E. Tollvir is made from natural ingredients qualified to provide strong 3CL protease inhibition in vitro, as well as strong anti-cytokine activity. Tollvir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollvir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed the rights of Tollvir to T-Cell Protect Hellas SA for the Greek market.

About Todos Medical Ltd.

Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs life-saving diagnostic solutions for the early detection of various cancers. The company’s state-of-the-art and patented Biochemical Infrared Assays (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that examines the influence of cancer on the immune system, looking for changes biochemicals in blood mononuclear cells and plasma. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos recently acquired US medical diagnostics company Provista Diagnostics, Inc. to obtain the rights to its Alpharetta, Georgia-based CLIA/CAP-certified laboratory, which currently performs COVID PCR tests and the breast cancer screening blood test. Videssa® exclusive to Provista at the commercial stage.

Todos also develops blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised cellular machinery that leads to aberrant cell cycle reentry by neurons, which then leads to apoptosis. LymPro is unique in using peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and brain neurons.

Todos formed the Israel-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March 2022 to consolidate all intellectual property pursuing the development of diagnostic tests targeting the 3CL protease, as well as protease inhibitor botanicals and pharmaceuticals 3CL that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through the Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid® in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollvir ®, while also developing the diagnostic 3CL protease inhibitor TolloTest™.

For more information, please visit https://www.todosmedical.com/.

Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based solely on the current expectations of management and are subject to important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties relating to the progress , timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional financing required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in the initiation of our clinical trials; changes in legislation; failure to develop and introduce new technologies, products and applications on a timely basis; lack of validation of our technology as we progress and lack of acceptance of our methods by the scientific community; the inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; cost of final product higher than expected; loss of market share and pressure on prices resulting from competition; and laboratory results that do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated by such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please see its reports filed from time to time with the United States Securities and Exchange Commission.

Company contact:
Daniel Hirsch
CFO
All medical
917-983-4229 ext. 104
[email protected]